FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer By Ogkologos - April 8, 2026 186 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the findings from the ROSELLA study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Seven Extra Years July 2, 2022 Brothers Break Down After Seeing Their Parents For First Time In... October 31, 2021 Coronavirus reports – Part 9: “I am very relieved but I... March 4, 2021 How to Find a Caregiver When You Have Cancer July 30, 2020 Load more HOT NEWS Reducing Health Care Disparities Through Cancer Clinical Trials FDA Approves Daratumumab and Hyaluronidase-fihj With Pomalidomide and Dexamethasone for Multiple... Physical Activity May Lessen the Effects of Chemobrain, Study Finds Ivosidenib and Azacitidine Combination Shows Significant Clinical Benefit in Patients with...
